Richard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of March, sparking further speculation about the unit’s future.
A digital therapeutic for irritable bowel syndrome, a developing world disease diagnosis tool, and a mobile maternity clinic in Uganda, were the three winners of Sandoz’s competition to imp
Novartis’ Sandoz subsidiary has taken its first steps into the emerging market for medical cannabis products, signing a global supply deal with Canadian producer Tilray.
A second mobile app developed by Pear Therapeutics to help opioid use disorder patients who have a more successful response to therapy has been given a green light by the FDA.